The Management of HCV Recurrence after Liver Transplantation.
10.4285/jkstn.2013.27.2.37
- Author:
Youngrok CHOI
1
;
Kwang Woong LEE
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. kwleegs@gmail.com
- Publication Type:Review
- Keywords:
HCV;
Immunosuppression;
Liver transplantation
- MeSH:
Antiviral Agents;
Cyclosporine;
Drug Interactions;
Hepacivirus;
Humans;
Immunosuppression;
Immunosuppressive Agents;
Korea;
Liver;
Liver Cirrhosis;
Liver Diseases;
Liver Transplantation;
Protease Inhibitors;
Quality of Life;
Recurrence;
Steroids;
Tacrolimus;
Transplants
- From:The Journal of the Korean Society for Transplantation
2013;27(2):37-41
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Liver transplantation (LT) for hepatitis C virus (HCV)-related liver diseases has been increasing in Korea. HCV recurrence, a serious complication after LT, can accelerate liver cirrhosis and fatal graft loss. Therefore, the prevention and appropriate treatment for HCV recurrence can improve a LT patient's quality of life and survival. In considering the relationship between immunosuppressants and HCV recurrence, there is no clear difference in HCV recurrence between the immunosuppressant tacrolimus or cyclosporine, and the use of steroids for patients with HCV is still under debate. In the management of HCV recurrence, direct-acting antivirals, such as protease inhibitors, polymerase inhibitors, or other nonstructural protein inhibitors will open a new era in HCV treatment. However, their safety and drug interactions with immunosuppressants should be evaluated for patients after LT.
